Swedish cancer immunotherapy company RhoVac AB (Spotlight:RHOVAC) announced on Monday that patient recruitment has been completed for its clinical phase IIb study of lead drug candidate RV001 in prostate cancer.
RhoVac started the BRaVac trial in late 2019, targeting prostate cancer patients with a biochemical recurrence (a rise in PSA) after curative intent therapy. In November 2020 RhoVac was awarded Fast Track Designation by the US Food and Drug Administration (FDA) for RV001 in this cancer indication.
The objective of the study is to show that RV001 can significantly prevent or delay disease progression in these patients, something for which no standard therapy is currently available.
Top-line results are estimated to be available in the first half of 2022.
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Oscotec receives ODD from FDA for Cevidoplenib
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
TELA Bio launches LIQUIFIX for US hernia surgery
BD boosts US syringe production amid healthcare demand
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT
Upgraded Syngene International biologics facility to start operation in 2024
BioXcel Therapeutics secures European patent for method to treat agitation in dementia